Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome

Stem Cells Translational Medicine

Guojun Bu¹  Abba C. Zubair¹  Wenchun Qu²  Erica Engelberg‐Cook²  Fred P. Sanfilippo³  Eva Kubrova⁴  Michael E. Wolf⁵  James C. Hill⁵  Vishal P. Shah⁵  Jorge M. Mallea⁶  Jorge M. Pascual⁶  Tarek Nayfeh⁷  M. Hassan Murad⁷  Zhen Wang⁷  Joshua M. Hare⁸  Joanne Kurtzberg⁹  Larry J. Prokop^1,10  Arnold I. Caplan^1,11 

[1] Center for Regenerative Medicine Mayo Clinic Jacksonville Florida USA;Department of Pain Medicine Mayo Clinic Jacksonville Florida USA;Department of Pathology and Laboratory Medicine, Department of Health Policy and Management Rollins School of Public Health, Emory University, The Marcus Foundation Atlanta Georgia USA;Department of Physical Medicine and Rehabilitation, Department of Orthopedic Surgery Mayo Clinic Rochester Minnesota USA;Department of Preventative, Occupational, and Aerospace Medicine Mayo Clinic Rochester Minnesota USA;Division of Pulmonary, Allergy and Sleep Medicine, Department of Medicine Mayo Clinic Jacksonville Florida USA;Evidence‐Based Practice Center Mayo Clinic Rochester Minnesota USA;Interdisciplinary Stem Cell Institute and Cardiology Division, Department of Medicine University of Miami, Miller School of Medicine Miami Florida USA;Marcus Center for Cellular Cures Duke University Medical Center Durham North Carolina USA;Mayo Clinic Library Rochester Minnesota USA;Skeletal Research Center, Biology Department Case Western Reserve University Cleveland Ohio USA;

关键词: acute respiratory distress syndrome;    COVID‐19;    mesenchymal stromal cells;    mortality;    systematic review;   

DOI  :  10.1002/sctm.20-0146

来源: DOAJ

【 摘 要 】

Abstract Severe cases of COVID‐19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID‐19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo‐capillary barriers. The authors performed a systematic literature review and random‐effects meta‐analysis to determine the potential value of MSC therapy for treating COVID‐19‐infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2/FiO2 ratio, alveolo‐capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.

【 授权许可】

Unknown